Comparison of in vitro Efficacy of Quinopristin /Dalfopristin, Linezolid and Vancomycin for Methicillin Resistant Staphylococcus Aureus

Posted on Author: .

About admin

Professor, Consultant Pathologist, American Board Certified Pathologist, Fellow College of American Pathologists. Areas of interest Fine Needle Aspiration Cytology, Cytology, Cancer, Ethics, Islam, Humanity

Comparison of in vitro Efficacy of Quinopristin /Dalfopristin, Linezolid and Vancomycin for Methicillin Resistant Staphylococcus Aureus

Faiqa Arshad*, Iffat Javed*, Tajammal Mustafa**, Sohaila Mushtaq*,
Saeed Anwer,*** Farida Rafique**
*Pathology Department, PGMI, Lahore, **Community Medicine Department, FJMC, Lahore,
*** Pathology Department, CMH, Lahore,

Abstract

Objectives: To compare the in vitro activity of quinopristin/dalfopristin, linezolid and vancomycin by determining their minimum inhibitory concentrations (MICs) for methicillin-resistant Staphylococcus aureus (MRSA) isolated from various clinical samples received from LGH, Lahore.
Study Design : Comparative Study
Place and Duration of Study: Pathology Department, Post Graduate Medical Institute, Lahore from February 2013 to October 2013.
Methodology: The MIC of quinopristin/dalfopristin, linezolid and vancomycin for 50 MRSA strains were determined by using E-test strips (AB Biodisk, Biomeurix) and results were interpreted according to clinical and laboratory standards institute (CLSI) guidelines.
Results: All the isolates showed 100% susceptibility to linezolid and quinopristin/dalfopristin and currently no resistant strain was found for these drugs. Quinopristin/dalfopristin showed lowest MIC values than Linezolid and vancomycin.
Conclusion: The study provided the in vitro information in establishing the role of linezolid and quinopristin/dalfopristin as an alternative to vancomycin for the treatment of serious MRSA infections. It also gives information regarding linezolid and quinopristin/dalfopristin as the best therapeutic option for the treatment of hVISA, VISA and VRSA.
Key Words: Methicillin Resistant Staphylococcus aureus, Minimum Inhibitory concentration, Epsilometer Test, heteroresistant Vancomycin Intermediate Staphylococcus aureus, Vancomycin Intermediate Staphylococcus aureus, Vancomycin Resistant Staphylococcus aureus, Clinical Laboratory and Standard Institute.

         

 Download PDF